ALVR vs. DTIL, GRTS, PLX, ATHA, CGTX, ATRA, ELUT, OTLK, JATT, and PASG
Should you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Precision BioSciences (DTIL), Gritstone bio (GRTS), Protalix BioTherapeutics (PLX), Athira Pharma (ATHA), Cognition Therapeutics (CGTX), Atara Biotherapeutics (ATRA), Elutia (ELUT), Outlook Therapeutics (OTLK), JATT Acquisition (JATT), and Passage Bio (PASG). These companies are all part of the "biological products, except diagnostic" industry.
AlloVir (NASDAQ:ALVR) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and community ranking.
AlloVir has a net margin of 0.00% compared to Precision BioSciences' net margin of -48.10%. AlloVir's return on equity of -98.50% beat Precision BioSciences' return on equity.
66.1% of AlloVir shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 33.9% of AlloVir shares are held by company insiders. Comparatively, 4.0% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
AlloVir has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.
Precision BioSciences received 61 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 67.18% of users gave Precision BioSciences an outperform vote while only 57.45% of users gave AlloVir an outperform vote.
Precision BioSciences has higher revenue and earnings than AlloVir. Precision BioSciences is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
In the previous week, Precision BioSciences had 1 more articles in the media than AlloVir. MarketBeat recorded 5 mentions for Precision BioSciences and 4 mentions for AlloVir. AlloVir's average media sentiment score of 0.94 beat Precision BioSciences' score of 0.91 indicating that AlloVir is being referred to more favorably in the media.
AlloVir presently has a consensus target price of $18.50, suggesting a potential upside of 2,350.33%. Precision BioSciences has a consensus target price of $46.33, suggesting a potential upside of 266.27%. Given AlloVir's higher probable upside, equities research analysts clearly believe AlloVir is more favorable than Precision BioSciences.
Summary
Precision BioSciences beats AlloVir on 9 of the 17 factors compared between the two stocks.
Get AlloVir News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
